approach to care delivery. This integrated and comprehensive approach will increase compliance to and effectiveness of treatment(s), resulting in improved patient and family outcomes.
Method: It is anticipated that the opportunity to offer families a "onestop" multidisciplinary approach to the management of severe eczema will improve patient outcomes and promote efficient use of the healthcare system. The team consists of a Paediatric Immunologist, Dermatologist, Paediatric Immunology Clinical Nurse Consultant, Paediatric Allergy Dietitian and Child Life Therapist. Families will leave with a consistent management approach to their child's eczema and receive adequate education to effectively implement the plan in the home environment. It is anticipated this will reduce the number of visits to hospital for outpatient appointments, and potential inpatient admissions. The project will provide baseline data related to the quality of life of children, adolescents and family as well as the associated burden of severe eczema.
Results: Quality of life, disease severity and impact, treatment compliance and patient and carer satisfaction data will be collected at the initial consultation, 6 months post initial review and 12 months post initial review. Data has been collected from the first three severe eczema clinics and will continue to be collected over the next 12-18months.
Conclusion: Data related to treatment outcomes will be attained and will be invaluable for ongoing quality improvement and research in the area. This will offer significant potential for prospective research projects in the area of eczema within our LHD, across LHD's and potentially national and internationally. We present the case of a 48 year old fisherman with a history of recurrent angioedema, without urticaria, following a severe stonefish envenomation. Angioedema predominantly affected the face and tongue, and had previously been anti-histamine responsive. However, over the last 12 months he had been suffering from an increase in both the severity and the frequency of episodes, with severe second daily facial swelling, 13 ED presentations for potential airway compromise and two ICU admissions, on at least one occasion requiring intubation. This had occurred despite an escalation in prophylactic therapy including H1 and H2 receptor antagonists, doxepin, montelukast and tranexamic acid with acute management including steroids, adrenaline and a bradykinin antagonist.
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During this time, he had extensive workup for a possible underlying driving process including dental extractions to exclude chronic infection, complement, tryptase, malignancy screening and autoimmune serology all of which were unremarkable. There was an incidental finding of an asymptomatic small primary spinal cord neoplasm which had been stable in size for over 6 months, not amenable to biopsy and of unknown significance to his condition.
A recent case series review of idiopathic non-histaminergic acquired angioedema showed complete response in twenty patients commenced on Omalizumab compared with the next most effective agent tranexamic acid. Tranexamic acid had a complete response in 27/107 patients and partial response in 97/107 patients. We obtained special approval for Omalizumab from our hospital Drug and Therapeutic Committee and the patient was commenced on Omalizumab 300mg monthly. He reported only 5 episodes of facial swelling over 7 weeks, none of which involved the tongue, with no ED presentations.
Our case study contributes to the growing evidence for use of Omalizumab to treat severe refractory idiopathic angioedema. Anti-neutrophil cytoplasmic antibodies (ANCAs) directed against PR3 and MPO are a valuable laboratory marker in the diagnosis and management of small vessel vasculitides. The 1999 international recommendations suggested screening with indirect immunofluorescence (IIF) with positive samples proceeding to antigen specific assays, which is the current practice in our laboratory. Given recent technical advances, the diagnostic performance of several antigen specific immunoassays was recently assessed in a European multicentre study and identified higher diagnostic accuracy than IIF. Therefore, the revised 2017 international Consensus recommendations suggest first line testing with antigen specific immunoassays for patients with suspected vasculitis.
We retrospectively reviewed all ANCA results performed by IIF and automated immunoassay (ELiA) over a 24 month period from our tertiary institution. Of the 7997 results, 6318 (79% were negative by IIF and did not proceed with further testing. 560 (7% of samples were requests for MPO/PR3 only (i.e. previously positive documented ANCA) and 560 (7% had IIF and MPO/PR3 results recorded on the same serum sample (i.e. first request for testing or clinician request). Of these, there was only one positive PR3 identified with a negative ANCA which was in a patient with treated GPA.
To model the impact of adopting the 2017 Consensus recommendations, we will prospectively analyse all samples from tertiary hospital requests for ANCA testing in our laboratory with first-line antigen specific immunoassay over several months. Our aim is to compare the diagnostic performance and cost-effectiveness in a tertiary hospital laboratory of initial screening by ANCA-IIF (current algorithm) with the recommendations for first-line antigen specific assay. Data collection is in progress and expected to be completed by July 2018.
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Background: The classic types of hereditary angioedema (HAE), types I and II, are caused by a deficiency of complement C1-inhibitor, due to mutations in the SERPING1 gene. Mutations in the coagulation factor XII (F12) gene have been identified as one cause of so-called 'HAE type III' ('HAE with normal C1 inhibitor'), explaining~25% of type III families. Here we describe the identification of a rare missense mutation of the plasminogen (PLG) gene representing the molecular basis for another subgroup of HAE type III.
Methods: Medical histories, pedigree information, and venous blood samples were obtained from members of ten 'HAE families with normal C1-inhibitor and no F12 mutation'. The PLG gene was screened for mutations using PCR and sequencing. Plasminogen protein was studied using isoelectric focusing and SDS-PAGE of plasma samples.
Results:
A rare non-conservative missense mutation was newly identified in exon 9 of the PLG gene. This mutation (c.1100A>G), encountered in 3 out of 10 unrelated patients, but not in controls, predicts a Lys-to-Glu substitution in position 311 of the mature protein, within the kringle 3 domain. In three large families co-segregation of the p.Lys311Glu mutation with the disease phenotype was observed. Immunoblotting studies demonstrated an aberrant plasminogen protein in plasma of mutation carriers. The mutation may create some kind of irregular and/or novel ligand interaction. Angioedema attacks of the tongue are the typical clinical manifestation of the novel HAE entity described here.
Conclusion:
The predicted structural and functional impact of the mutation, its absence in controls, and its co-segregation with the phenotype, provide strong support that the p.Lys311Glu mutation and the corresponding dysplasminogenemia cause disease and that the PLG gene is a new angioedema gene. The term 'HAE type C' may be used for a hereditary angioedema caused by a mutation of the plasminogen gene. 
